Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.5.0.2
Consolidated Statements of Operations - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Revenue:        
Lymphoseek sales revenue $ 4,231,719 $ 1,963,548 $ 8,014,399 $ 3,798,970
Lymphoseek license revenue 245,950 250,000 500,000 333,333
Grant and other revenue 916,811 654,360 1,602,636 844,061
Total revenue 5,394,480 2,867,908 10,117,035 4,976,364
Cost of goods sold 560,740 332,730 1,095,669 781,787
Gross profit 4,833,740 2,535,178 9,021,366 4,194,577
Operating expenses:        
Research and development 2,525,581 2,297,074 5,185,101 6,278,362
Selling, general and administrative 2,888,141 4,048,799 6,984,801 9,542,967
Total operating expenses 5,413,722 6,345,873 12,169,902 15,821,329
Income (loss) from operations (579,982) (3,810,695) (3,148,536) (11,626,752)
Other income (expense):        
Interest expense, net (7,528,475) (1,575,741) (9,721,998) (2,542,317)
Equity in loss of R-NAV, LLC (2,920) (6,205) (15,159) (268,432)
Loss on disposal of investment in R-NAV, LLC (39,732)   (39,732)  
Change in fair value of financial instruments 1,469,928 (1,852,730) 2,595,287 (125,627)
Loss on extinguishment of debt   (2,440,714)   (2,440,714)
Other, net (126) (4,834) (37,418) 21,698
Total other expense, net (6,101,325) (5,880,224) (7,219,020) (5,355,392)
Net income (loss) (6,681,307) (9,690,919) (10,367,556) (16,982,144)
Less loss attributable to noncontrolling interest (116) (241) (357) (341)
Deemed dividend on beneficial conversion feature of MT Preferred Stock       (46,000)
Net loss attributable to common stockholders $ (6,681,191) $ (9,690,678) $ (10,367,199) $ (17,027,803)
Loss per common share (basic and diluted) $ (0.04) $ (0.06) $ (0.07) $ (0.11)
Weighted average shares outstanding (basic and diluted) 155,382,368 150,107,148 155,345,231 149,951,603